Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling

Bibliography

• Camidge DR. Icotinib: kick-starting the Chinese anticancer drug industry. Lancet Oncol 2013;14(10):913-14
   PubMed Web of Science ®Google Scholar
• Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012;76(2):177-82
   PubMed Web of Science ®Google Scholar
• Gao Z, Chen W, Zhang X, et al. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling. Biomed Pharmacother 2013;67(5):351-6
   PubMed Web of Science ®Google Scholar
• Mu X, Zhang Y, Qu X, et al. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Biomed Res Int 2013;2013:726375
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14(10):953-61
   PubMed Web of Science ®Google Scholar
• Shao L, Zhang B, He C, et al. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy. Chin Med J (Engl) 2014;127(2):266-71
   PubMed Web of Science ®Google Scholar
• Wang HP, Zhang L, Wang YX, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 2011;124(13):1933
   PubMed Web of Science ®Google Scholar
• Zhao Q, Shentu J, Xu N, et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011;73(2):195-202
   PubMed Web of Science ®Google Scholar
• Liu D, Jiang J, Zhang L, et al. Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects. Cancer Chemother Pharmacol 2014;73(4):721-7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Court MH, et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000;28(12):1493-504
   PubMed Web of Science ®Google Scholar
• Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005;94(6):1259-76
   PubMed Web of Science ®Google Scholar
• Huang J, Jacobson P, Brundage R. Prediction of unbound mycophenolic acid concentrations in patients after hematopoietic cell transplantation. Ther Drug Monit 2007;29(4):385-90
   PubMed Web of Science ®Google Scholar
• Clarke SE. In vitro assessment of human cytochrome P450. Xenobiotica 1998;28(12):1167-202
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999;57(5):465-80
   PubMed Web of Science ®Google Scholar
• Crespi CL, Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997;43:171-88
   PubMedGoogle Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 2011;39(4):591-602
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker G. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug-drug interactions. Drug Discov Today Technol 2004;1(4):441-8
   PubMedGoogle Scholar
• Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45(5):511-42
   PubMed Web of Science ®Google Scholar
• Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
   PubMed Web of Science ®Google Scholar
• Clewell HJIII, Lee TS, Carpenter RL. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal 1994;14(4):521-31
   PubMed Web of Science ®Google Scholar
• Evans MV, Crank WD, Yang HM, Simmons JE. Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. Toxicol Appl Pharmacol 1994;128(1):36-44
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Mäenpää J, Taavitsainen P, et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998;28(12):1203-53
   PubMed Web of Science ®Google Scholar
• Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5’-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos 2014;42(4):500-10
   PubMed Web of Science ®Google Scholar
• Brandon EF, Raap CD, Meijerman I, et al. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003;189(3):233-46
   PubMed Web of Science ®Google Scholar
• Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 2003;42(2):153-78
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 2001;297(1):326-37
   PubMed Web of Science ®Google Scholar
• Yang J, Liao M, Shou M, et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008;9(5):384-94
   PubMed Web of Science ®Google Scholar
• Ruan CJ, Liu DY, Jiang J, Hu P. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. Eur J Clin Pharmacol 2012;68(12):1677-80
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011;89(2):259-67
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, et al. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5(2):211-23
   PubMed Web of Science ®Google Scholar
• Gabrielsson JL, Groth T. An extended physiological pharmacokinetic model of methadone disposition in the rat: validation and sensitivity analysis. J Pharmacokinet Biopharm 1988;16(2):183-201
   PubMedGoogle Scholar